Literature DB >> 30107021

Disease-modifying therapies for nonrelapsing multiple sclerosis: Absence of evidence does not constitute evidence of absence.

Jeffrey Dunn1.   

Abstract

Entities:  

Year:  2013        PMID： 30107021      PMCID： PMC6082359          DOI： 10.1212/01.CPJ.0000436215.95884.89

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  6 in total

1.  Evidence-based medicine. A new approach to teaching the practice of medicine.

Authors: 
Journal:  JAMA       Date:  1992-11-04       Impact factor: 56.272

2.  The American Academy of Neurology's top five choosing wisely recommendations.

Authors:  Annette M Langer-Gould; Wayne E Anderson; Melissa J Armstrong; Adam B Cohen; Matthew A Eccher; Donald J Iverson; Sonja B Potrebic; Amanda Becker; Rod Larson; Alicia Gedan; Thomas S D Getchius; Gary S Gronseth
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

3.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

4.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

5.  Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.

Authors:  Jerry S Wolinsky; Ponnada A Narayana; Paul O'Connor; Patricia K Coyle; Corey Ford; Kenneth Johnson; Aaron Miller; Lillian Pardo; Shaul Kadosh; David Ladkani
Journal:  Ann Neurol       Date:  2007-01       Impact factor: 10.422

Review 6.  Interferon Beta for primary progressive multiple sclerosis.

Authors:  Juan Ignacio Rojas; Marina Romano; Agustín Ciapponi; Liliana Patrucco; Edgardo Cristiano
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.